# Treatment Methods for Cardiomyopathy
The treatment of cardiomyopathy varies greatly depending on the type and stage of the disease. The objectives are usually: to improve or stabilize the pumping function of the heart, to relieve symptoms, to reduce the risk of sudden cardiac death, and to prevent heart rhythm disturbances.
Medications for Heart Failure and Pumping
ACE Inhibitors and Angiotensin Receptor Blockers (ARBs) ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications widen blood vessels and reduce the workload of the heart. They are widely used in dilated cardiomyopathy (where the heart is enlarged) and help protect the heart muscle from further damage. Side effects can include cough, dizziness, and kidney dysfunction. Regular monitoring of blood pressure and kidney function is necessary.
Beta-Blockers ProveniIncluded in official guidelines, or approved by EMA or FDA
These slow the heart rate and reduce the force with which the heart contracts, which decreases the oxygen demand of the heart muscle. They play a role in many forms of cardiomyopathy. Possible side effects are fatigue, slow heart rate, and impotence.
Aldosterone Antagonists ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications help prevent fluid accumulation and protect the heart against certain forms of damage. They are used especially in combination with ACE inhibitors or ARBs. Elevated potassium levels must be monitored.
SGLT2 Inhibitors ProveniIncluded in official guidelines, or approved by EMA or FDA
This group of medications, originally developed for diabetes, has also been shown to protect the heart. Studies show that they improve symptoms and reduce hospitalizations in many patients with heart failure, regardless of whether diabetes is present. Side effects are generally mild and may include urinary tract infections.
Ivabradine ResearchediPositive results in clinical studies, not yet standard treatment
This medication lowers the heart rate without directly affecting heart muscle contraction. It is being investigated as support in certain forms of cardiomyopathy, particularly when beta-blockers are not well tolerated or are insufficient.
Medications for Rhythm and Prevention of Sudden Death
Antiarrhythmic Medications ProveniIncluded in official guidelines, or approved by EMA or FDA
These are used when serious rhythm disturbances occur (heart rhythm disorders). The goal is to reduce the risk of sudden cardiac death. Some of these can have side effects such as dizziness, fatigue, or organic complications and require regular monitoring.
Implantable Cardioverter-Defibrillator (ICD) ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a device (approximately the size of a watch band) that is implanted under the skin, usually under the collarbone. It continuously monitors the heart rhythm and delivers an electrical shock for life-threatening rhythms to restore normal rhythm. For many patients with dilated cardiomyopathy and high risk of sudden cardiac death, this is a standard treatment. Complications can include infection, electrode malfunction, or repositioning.
Cardiac Resynchronization Therapy (CRT) ProveniIncluded in official guidelines, or approved by EMA or FDA
This device (sometimes combined with a defibrillator) sends electrical impulses to both heart chambers to allow them to work synchronously again. This especially helps patients with severely weakened heart function and delayed conduction. It can improve symptoms and prolong survival. Side effects are rare, but can include electrode dislodging or infection.
Targeted Therapies
Mavacamten ProveniIncluded in official guidelines, or approved by EMA or FDA
This medication is specific for obstructive hypertrophic cardiomyopathy (where the heart tissue is thickened). It reduces the binding force of certain proteins in the heart muscle, thereby decreasing the narrowing and improving blood flow. Clinical studies show improvement in symptoms and reduced obstruction. Side effects include low hemoglobin and elevated troponin (heart markers), which require regular monitoring.
Vericiguat ResearchediPositive results in clinical studies, not yet standard treatment
This medication targets certain inflammatory pathways that play a role in chronic heart failure. Studies show promising results in reducing hospitalizations, especially in patients with recurrent fluid accumulation.
Dietary Measures and Lifestyle
Sodium restriction ProveniIncluded in official guidelines, or approved by EMA or FDA
Limiting salt intake helps prevent fluid accumulation and can reduce symptoms such as shortness of breath and swelling.
Fluid intake and weight monitoring ProveniIncluded in official guidelines, or approved by EMA or FDA
For certain forms of cardiomyopathy, it is recommended to monitor weight daily, as rapid weight gain (more than 2-3 kg in a few days) may indicate fluid accumulation. Adjustments to medication may then be necessary.
Invasive procedures and surgery
Heart implantation (heart transplantation) ProveniIncluded in official guidelines, or approved by EMA or FDA
This is the ultimate treatment option for end-stage dilated cardiomyopathy when medications no longer help. It gives patients a considerably longer and more active lifespan. After transplantation, lifelong immunosuppressants are needed to prevent rejection, and regular check-ups remain essential. The availability of donor organs is limited.
Left ventricular assist devices (LVAD) ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a mechanical pump that supports the left chamber of the heart and pumps blood through the body. It can serve as a 'bridge' to transplantation or in some cases as durable long-term support. It improves symptoms and can prolong survival. Possible complications include infection, bleeding, and thrombosis.
Surgical myectomy or ablation ProveniIncluded in official guidelines, or approved by EMA or FDA
In obstructive hypertrophic cardiomyopathy, surgical removal of thickened heart muscle (myectomy) or catheterization with alcohol ablation can reduce the obstruction. This is done especially if medications help insufficiently and symptoms are severe. The risk of arrhythmias remains.
Supportive treatments
Diuretics (water pills) ProveniIncluded in official guidelines, or approved by EMA or FDA
These reduce fluid accumulation in the lungs and body, relieving shortness of breath and swelling. Frequent use requires monitoring of fluid balance and electrolytes.
Anticoagulants (blood thinners) ProveniIncluded in official guidelines, or approved by EMA or FDA
In certain forms of cardiomyopathy, especially if there is severe reduced pump function, there is an increased risk of blood clots. Blood thinning helps prevent this.
Experimental approaches
Gene therapies and cell therapy ExperimentaliOngoing in study setting, outcome still unknown
Research is exploring possibilities to address defective genes (such as in certain hereditary forms with mutations in titin or other heart proteins) or repair damaged heart tissue with specialized cells. This is still largely in the research phase.
NVC-001 (LMNA cardiomyopathy) ResearchediPositive results in clinical studies, not yet standard treatment
For the rare form caused by LMNA gene mutations, new therapies are being investigated in clinical trials. These focus on stabilizing specific heart functions.
Metabolic interventions ResearchediPositive results in clinical studies, not yet standard treatment
New research points to possible roles for GLP-1 agonists and other metabolic approaches, especially in cardiomyopathy related to diabetes. This is still in the research stage.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._